| Entry |
|
|---|
| Name |
Valproic acid (USP);
Depakene (TN) |
|---|
| Product |
|
|---|
| Generic |
VALPROIC (Actavis Pharma), VALPROIC (Aphena Pharma Solutions - Tennessee), VALPROIC ACID (ANI Pharmaceuticals), VALPROIC ACID (ATLANTIC BIOLOGICALS CORP.), VALPROIC ACID (ATLANTIC BIOLOGICALS CORP.), VALPROIC ACID (Aphena Pharma Solutions - Tennessee), VALPROIC ACID (Aphena Pharma Solutions - Tennessee), VALPROIC ACID (Bionpharma), VALPROIC ACID (Bryant Ranch Prepack), VALPROIC ACID (Bryant Ranch Prepack), VALPROIC ACID (Chartwell RX), VALPROIC ACID (Lannett Company), VALPROIC ACID (McKesson Corporation dba SKY Packaging), VALPROIC ACID (McKesson Corporation dba SKY Packaging), VALPROIC ACID (NCS HealthCare of KY), VALPROIC ACID (NorthStar Rx LLC), VALPROIC ACID (PAI Holdings), VALPROIC ACID (QUAGEN PHARMACEUTICALS LLC), VALPROIC ACID (REMEDYREPACK), VALPROIC ACID (REMEDYREPACK), VALPROIC ACID (Upsher-Smith Laboratories) |
|---|
| Formula |
C8H16O2
|
|---|
| Exact mass |
144.1150
|
|---|
| Mol weight |
144.21
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Cardiovascular agent
DG01575 Calcium channel blocker
DG01573 Calcium channel T type blocker
Neuropsychiatric agent
DG03199 Antiepileptic agent
DG02035 Fatty acid antiepileptic
|
|---|
| Remark |
| Product (DG00849): | D00399<US> D00304<US> D00710<JP/US> |
|
|---|
| Efficacy |
Anticonvulsant |
|---|
| Comment |
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Interaction |
|
|---|
| Structure map |
|
|---|
| Other map |
| map00982 | Drug metabolism - cytochrome P450 |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N03 ANTIEPILEPTICS
N03A ANTIEPILEPTICS
N03AG Fatty acid derivatives
N03AG01 Valproic acid
D00399 Valproic acid (USP) <US>
USP drug classification [BR:br08302]
Anticonvulsants
Anticonvulsants, Other
Valproic Acid
D00399 Valproic acid (USP)
Antimigraine Agents
Antimigraine Agents, Other
Valproic Acid
D00399 Valproic acid (USP)
Bipolar Agents
Mood Stabilizers
Valproic Acid
D00399 Valproic acid (USP)
Drug groups [BR:br08330]
Cardiovascular agent
DG01575 Calcium channel blocker
DG01573 Calcium channel T type blocker
DG00849 Valproic acid
D00399 Valproic acid
Neuropsychiatric agent
DG03199 Antiepileptic agent
DG02035 Fatty acid antiepileptic
DG00849 Valproic acid
D00399 Valproic acid
Drug classes [BR:br08332]
Neuropsychiatric agent
DG03199 Antiepileptic agent
D00399 Valproic acid
Target-based classification of drugs [BR:br08310]
Ion channels
Voltage-gated ion channels
Calcium channels
CACNA1-T
D00399 Valproic acid (USP) <US>
Enzymes
Oxidoreductases (EC1)
Dehydrogenases
SSADH
D00399 Valproic acid (USP) <US>
Transferases (EC2)
Aminotransferase
ABAT
D00399 Valproic acid (USP) <US>
Lyases (EC4)
Carboxy-lyases
GAD
D00399 Valproic acid (USP) <US>
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D00399
Drug groups [BR:br08330]
Cardiovascular agent
DG01575 Calcium channel blocker
DG01573 Calcium channel T type blocker
DG00849 Valproic acid
Neuropsychiatric agent
DG03199 Antiepileptic agent
DG02035 Fatty acid antiepileptic
DG00849 Valproic acid
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 10
1 C1c C 25.4573 -18.6784
2 C1b C 25.4573 -17.3002
3 C1b C 24.2485 -19.3967
4 C6a C 26.6604 -19.3967
5 C1b C 24.2427 -16.5935
6 C1b C 23.0396 -18.6784
7 O6a O 26.6604 -20.7925
8 O6a O 27.8692 -18.6784
9 C1a C 23.0339 -17.3002
10 C1a C 21.8367 -19.3967
BOND 9
1 1 2 1
2 1 3 1
3 1 4 1
4 2 5 1
5 3 6 1
6 4 7 1
7 4 8 2
8 5 9 1
9 6 10 1
|
|---|